Revision Fusion and Long-Term Analgesic Burden: Reporting from a Recent Cohort Summary

A recent report described similar early postoperative opioid use after primary versus revision elective 1–3 level lumbar fusion, with prescribing trajectories separating over longer follow-up. The report describes analysis of state prescription drug monitoring program (PDMP) data with checkpoints from 30 days through 2 years after surgery. Early postoperative patterns were not presented as strongly distinguishing the groups, while later windows were.

The summary reports a retrospective cohort of 1,938 patients (1,498 primary fusions; 440 revision fusions), using PDMP data to compare opioid and gabapentinoid prescriptions at 30 days, 90 days, 1 year, and 2 years. It describes opioid use as similar through the first 30 days, then contrasts opioid burden thereafter using morphine milligram equivalents (MME). At 90 days, revision cases were reported to have higher cumulative MME than primary cases (428 vs 219), with larger differences reported at 1 year (1,142 vs 382) and 2 years (1,550 vs 497). Presented this way, the divergence was described as widening as follow-up extended from months into years, with separation emerging after the immediate postoperative period and increasing across later checkpoints.

Beyond opioids, the study reports higher gabapentinoid prescribing in revision patients by 90 days (19.3% vs 13.4%). It also describes multivariable modeling in which preoperative opioid exposure was identified as the strongest predictor of prolonged opioid use, while revision status was reported to remain an independent predictor at 1 and 2 years. The authors’ interpretation was that the non-opioid prescribing differences and longer-term opioid persistence could be consistent with a more neuropathic or otherwise complex pain phenotype among revision patients. In that narrative, predictors and medication patterns are linked as complementary signals of persistent postoperative pain biology rather than only perioperative prescribing variation.

For perioperative planning discussions, the report frames these findings as context on which variables tracked before surgery and which follow-up horizons after surgery were associated with different prescribing trajectories. It emphasizes baseline opioid exposure and revision status as the clearest reported signals separating longer-term patterns, while early postoperative use appeared less differentiating in the presented comparison. The time scale of interest is also placed beyond routine early follow-up, because the largest differences were described at later checkpoints. In this cohort, revision status and baseline opioid exposure were reported as being linked with higher long-term analgesic prescribing over months to years.

Key Takeaways:

• A time-dependent divergence in cumulative opioid prescribing was reported after revision versus primary lumbar fusion, with separation emerging after the early postoperative window and increasing across later follow-up.
• Gabapentinoid prescribing was reported to be higher by 90 days among revision patients than primary patients in the summarized cohort.
• Multivariable analysis reportedly identified baseline opioid exposure as the strongest predictor of prolonged opioid use, with revision status remaining an independent predictor at longer-term checkpoints.